Biomet Gets FDA Approval
BY SHELLY ACHAIBAR, JANUARY 6, 2006
Biomet received FDA approval for the C2a-Taper Acetabular System, a ceramic-on-ceramic hip replacement system. Biomet's FDA approval follows Stryker, Wright Medical, Encore Medical, Smith & Nephew and Zimmer.
President and CEO Dane A. Miller, Ph.D. stated, "We are pleased to announce receipt of the regulatory approval for Biomet's C2a-Taper™ Acetabular System. Biomet's ceramic-on-ceramic system offers surgeons a great alternative-bearing product, coupled with the Company's proven porous plasma spray coating technology for excellent long-term fixation."
With the addition of the C2a system, Biomet now offers one of the most expansive hip product lines in the industry. The hip product line uses a variety of components such as cemented versus cement-free, porous coating, and femoral and acetabular components.
Biomet is also conducting U.S. clinical trials for the ReCap Total Hip Resurfacing System. This is an alternative to total hip replacement surgery and recommended for slightly younger, more active patients. This procedure is currently approved in Europe and Asia, refer to our article on Medical Tourism.
